Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Thumbnail

Ozone, other pollutants increase odds of emphysema

Long-term exposure to ambient air pollutants—especially ozone—increase a person’s chance of developing emphysema, according to research published August 13 in JAMA.

Thumbnail

Mobile stroke units get patients to hospital faster than ambulances

Transport to the hospital via mobile stroke unit—as opposed to standard transit in an ambulance—saved stroke victims 10 minutes and up to 270 million neurons in a study out of the University of Texas Health Science Center at Houston.

Thumbnail

Endovascular-first approach boosts amputation-free survival in patients with critical limb ischemia

Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

Thumbnail

Update: FDA acknowledges late mortality signal with paclitaxel devices

The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

Thumbnail

‘Heart-on-a-chip’ system replicates human drug response

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

Thumbnail

NSAIDs heighten CV risk in patients with osteoarthritis

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.

JUUL Labs: A case study in ethical vaping research

An editorial published in The Lancet August 2 scrutinized JUUL Labs’ participation in and sponsorship of e-cigarette research in the U.S., finding the vaping giant fell short in seven of eight categories designed to test ethical integrity.

Thumbnail

Hep C hikes risk of CVD by 28%

Individuals infected with hepatitis C are at a significantly increased risk of developing heart disease, according to a Lancet analysis that also found hep C-linked CVD is responsible for 1.5 million disability-adjusted life-years (DALYs) annually.